EE256 Comparative Cost-Utility Analysis of Galcanezumab and Fremanezumab for Migraine Prevention in Individuals with Chronic Migraine Who Have Tried 2 to 4 Prior Preventive Treatments
Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.557
https://www.valueinhealthjournal.com/article/S1098-3015(23)00657-5/fulltext
Title :
EE256 Comparative Cost-Utility Analysis of Galcanezumab and Fremanezumab for Migraine Prevention in Individuals with Chronic Migraine Who Have Tried 2 to 4 Prior Preventive Treatments
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)00657-5&doi=10.1016/j.jval.2023.03.557
First page :
Section Title :
Open access? :
No
Section Order :
10039